[go: up one dir, main page]

MX384262B - Gel intestinal de levodopa y carbidopa y metodos de uso. - Google Patents

Gel intestinal de levodopa y carbidopa y metodos de uso.

Info

Publication number
MX384262B
MX384262B MX2017009325A MX2017009325A MX384262B MX 384262 B MX384262 B MX 384262B MX 2017009325 A MX2017009325 A MX 2017009325A MX 2017009325 A MX2017009325 A MX 2017009325A MX 384262 B MX384262 B MX 384262B
Authority
MX
Mexico
Prior art keywords
methods
levodopa
pharmaceutical composition
intestinal gel
carbidopa
Prior art date
Application number
MX2017009325A
Other languages
English (en)
Other versions
MX2017009325A (es
Inventor
Alexandru Deac
Jayne B Zimmerman
Rajkumar Conjeevaram
Randy A Menges
Sean E Mackey
Ye Huang
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2017009325A publication Critical patent/MX2017009325A/es
Publication of MX384262B publication Critical patent/MX384262B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

La presente divulgación se refiere a (a) una composición farmacéutica mejorada que comprende un agente activo de levodopa y un agente activo de carbidopa, (b) métodos de producir la composición farmacéutica y (c) métodos de tratar la enfermedad de Parkinson y afecciones asociadas, que comprende administrar la composición farmacéutica a un sujeto con enfermedad de Parkinson.
MX2017009325A 2015-01-20 2016-01-20 Gel intestinal de levodopa y carbidopa y metodos de uso. MX384262B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562105565P 2015-01-20 2015-01-20
US201562272922P 2015-12-30 2015-12-30
PCT/US2016/014005 WO2016118556A1 (en) 2015-01-20 2016-01-20 Levodopa and carbidopa intestinal gel and methods of use

Publications (2)

Publication Number Publication Date
MX2017009325A MX2017009325A (es) 2018-02-09
MX384262B true MX384262B (es) 2025-03-14

Family

ID=55410198

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009325A MX384262B (es) 2015-01-20 2016-01-20 Gel intestinal de levodopa y carbidopa y metodos de uso.

Country Status (16)

Country Link
US (3) US10117843B2 (es)
EP (2) EP3247330A1 (es)
JP (4) JP2018503686A (es)
KR (1) KR20170103967A (es)
CN (2) CN107427463A (es)
AU (1) AU2016209420B2 (es)
BR (1) BR112017015613B1 (es)
CA (1) CA2974203A1 (es)
IL (1) IL253487A0 (es)
MA (1) MA41377A (es)
MX (1) MX384262B (es)
PH (1) PH12017501304A1 (es)
RU (1) RU2017129375A (es)
SG (1) SG11201705964YA (es)
TW (1) TW201639556A (es)
WO (1) WO2016118556A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2965379A1 (en) 2014-10-21 2016-04-28 Abbvie Inc. Carbidopa and l-dopa prodrugs and methods of use
MA41377A (fr) * 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
KR20180004756A (ko) 2015-05-06 2018-01-12 신애질 코포레이션 약물 입자를 함유하는 제약 현탁액, 그의 투여를 위한 장치, 및 그의 사용 방법
MX2019000849A (es) * 2016-07-20 2019-09-13 Abbvie Inc Gel intestinal de levodopa y carbidopa y metodos de uso.
AU2019379806B2 (en) 2018-11-15 2025-08-14 Abbvie Inc. Pharmaceutical formulations for subcutaneous administration
CN119510592A (zh) * 2023-08-22 2025-02-25 上海汉都医药科技有限公司 一种含有卡比多巴的药物中肼含量的检测方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132171A (en) 1962-06-18 1964-05-05 Strong Cobb Arner Inc 3, 4-diphosphatophenyl-alanine and process for making same
US4618484A (en) 1983-03-30 1986-10-21 Yale University Composition and method for treatment of melanomas
ATE118216T1 (de) 1989-04-20 1995-02-15 Zambon Spa Dopamin-medikament-vorstufe.
IT1255471B (it) 1992-07-30 1995-11-02 Zambon Spa Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono
SE9203594D0 (sv) * 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US6365180B1 (en) 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
WO2004069146A2 (en) 2003-02-07 2004-08-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-dopa amide derivatives and uses thereof
CN101636145B (zh) 2006-05-31 2014-04-23 雅培产品有限公司 长期24小时经肠给予左旋多巴/卡比多巴
EP3777839A1 (en) 2009-05-19 2021-02-17 Neuroderm Ltd Compositions for continuous administration of dopa decarboxylase inhibitors
US20130253056A1 (en) 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
WO2011056240A2 (en) 2009-11-09 2011-05-12 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
NZ610911A (en) * 2010-11-15 2015-02-27 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
BR112013014304A2 (pt) * 2010-12-10 2016-07-19 Synagile Corp composições de pró-fármaco levodopa infundíveis subcutaneamente e método de infusão
US8765189B2 (en) 2011-05-13 2014-07-01 Howmedica Osteonic Corp. Organophosphorous and multivalent metal compound compositions and methods
WO2013033453A2 (en) 2011-08-31 2013-03-07 Abbott Laboratories Sealing arrangement for syringe
US20160022573A1 (en) 2013-03-13 2016-01-28 Neuroderm, Ltd. Method for treatment of parkinson's disease
JP6538063B2 (ja) 2013-11-05 2019-07-03 シンアジャル コーポレイション 口を介する連続的薬物送達のためのデバイスおよび方法
MA41377A (fr) * 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation

Also Published As

Publication number Publication date
EP4470611A2 (en) 2024-12-04
IL253487A0 (en) 2017-09-28
JP2023058678A (ja) 2023-04-25
RU2017129375A3 (es) 2019-08-05
JP7232235B2 (ja) 2023-03-02
US20190142777A1 (en) 2019-05-16
RU2017129375A (ru) 2019-02-21
JP2021073186A (ja) 2021-05-13
CN116036064A (zh) 2023-05-02
AU2016209420A1 (en) 2017-08-03
PH12017501304A1 (en) 2018-02-05
BR112017015613B1 (pt) 2023-11-28
KR20170103967A (ko) 2017-09-13
AU2016209420B2 (en) 2021-05-20
JP2024129122A (ja) 2024-09-26
US10117843B2 (en) 2018-11-06
TW201639556A (zh) 2016-11-16
JP2018503686A (ja) 2018-02-08
MA41377A (fr) 2017-11-28
CN107427463A (zh) 2017-12-01
CA2974203A1 (en) 2016-07-28
MX2017009325A (es) 2018-02-09
US20210046029A1 (en) 2021-02-18
SG11201705964YA (en) 2017-08-30
EP3247330A1 (en) 2017-11-29
WO2016118556A1 (en) 2016-07-28
EP4470611A3 (en) 2025-02-19
US20160206584A1 (en) 2016-07-21
BR112017015613A2 (en) 2018-03-13

Similar Documents

Publication Publication Date Title
MX2021003840A (es) Profarmacos de carbidopa y l-dopa y metodos de uso.
CO2019013707A2 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson
WO2017184871A9 (en) Carbidopa and l-dopa prodrugs and methods of use
MX384262B (es) Gel intestinal de levodopa y carbidopa y metodos de uso.
JOP20200230A1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
MX384429B (es) Formulaciones de aminoácidos de liberación modificada administradas por vía oral.
MX2023010501A (es) Profarmacos de dantroleno y metodos de su uso.
MX386055B (es) Uso de medicamentos para disminuir la evolución de la enfermedad de parkinson.
JOP20210269A1 (ar) تركيبة دوائية مائية لجسم مضاد ضد-il17a واستخدامها
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
EA202191686A1 (ru) Гидролизат коллагена для применения против кожных болезней и кишечных заболеваний
MX2022014577A (es) Gel intestinal de levodopa y carbidopa y metodos de uso.
MX2018002298A (es) Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.
IN2013MU02576A (es)
MX2022001772A (es) Formulaciones de isotretinoina y usos y metodos de las mismas.
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
WO2018128722A8 (en) Use of gut microbiota in the diagnosis and therapeutics of parkinson's disease
MX2025002392A (es) Formulaciones de dantroleno y metodos de uso de dichas formulaciones
HK1245638A1 (en) Levodopa and carbidopa intestinal gel and methods of use
AR103448A1 (es) Gel intestinal de levodopa y carbidopa y métodos de uso
BR112019002792A2 (pt) compostos de fumagilol e métodos de fabricar e usar os mesmos
UA106471U (uk) Засіб для лікування дерматологічних захворювань
IN2013MU02575A (es)
EA201690113A1 (ru) Везикулы
UA106472U (uk) Засіб для лікування дерматологічних захворювань